PureTech Health (LON:PRTC) Shares Up 14.2% - Should You Buy?

Key Points

• PureTech Health shares rose by 14.2% on Friday, with trading volumes significantly up at approximately 9 million shares.
• The company's market cap stands at £293.65 million, while it has a high PE ratio of 714.71 and a debt-to-equity ratio of 45.82.
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1, reflecting confidence in the company's potential.

PureTech Health plc (LON:PRTC - Get Free Report) was up 14.2% during trading on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Trading Down 0.2%

The stock has a fifty day moving average of GBX 129.31 and a 200 day moving average of GBX 129.65. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The company has a market capitalization of £302.59 million, a PE ratio of 736.47 and a beta of 1.02.

Insider Activity

In other news, insider Bharatt Chowrira acquired 167,739 shares of the firm's stock in a transaction dated Thursday, July 3rd. The shares were acquired at an average cost of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is owned by company insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.